Trending...
- DARPA Selects NRx Pharmaceuticals Defense Subsidiary for Contract Negotiations on FDA-Authorized SPARC-TMS Clinical Trial Advancing Mental Health Care - 171
- From the Racetrack to the Boardroom: Aston Martin and Aramco Formula One Partnership Accelerates Circle8 Group: (N A S D A Q: CIRC) - 149
- Cover Story about Matthew Cossolotto – Author of Harness Your PromisePower -- Published in July 2026 Enterprise World Magazine - 108
New preclinical research reports that HuMOLYTE®, a magnesium-containing medical food with 2′-fucosyllactose, reduced chemotherapy-induced gastrointestinal and oral mucosal injury in Wistar rats
SACRAMENTO, Calif. - Michimich -- IGH Naturals announced that a peer-reviewed original research study evaluating HuMOLYTE® has been accepted and published in Frontiers in Nutrition. The study, titled "Supplementation with 2′-fucosyllactose, a prebiotic human milk oligosaccharide (HMO), in a magnesium-containing medical food reduces chemotherapy-induced mucositis in Wistar rats," reports preclinical findings on HuMOLYTE®, a medical food formulated with 2′-fucosyllactose, magnesium, sodium, and potassium.
Chemotherapy-induced mucositis is a common and difficult side effect of cancer treatment that can affect the mouth and gastrointestinal tract. It may contribute to painful oral symptoms, diarrhea, dehydration, electrolyte loss, poor nutrition, and interruptions in treatment. For patients and caregivers, these complications can add physical and emotional strain during an already challenging time.
More on Michimich.com
The newly published study evaluated HuMOLYTE® in Wistar rats exposed to commonly used chemotherapy agents, including doxorubicin, irinotecan, 5-fluorouracil, and cisplatin. According to the publication, HuMOLYTE® supplementation was associated with reduced severity of chemotherapy-induced diarrhea, less chemotherapy-associated weight loss, and preservation of gastrointestinal mucosal structure, including goblet cells.
The study also reported reduced inflammation in ileal, colonic, and oral mucosal tissue among animals supplemented with HuMOLYTE®. In laboratory cell studies, HuMOLYTE® improved goblet cell survival, supported mucin secretion, and helped maintain epithelial barrier function.
"This publication marks an important milestone for IGH Naturals and HuMOLYTE®," said Dr. Sourabh Kharait, corresponding author of the study. "While these findings are preclinical and require confirmation in human clinical trials, they provide a strong scientific foundation for further investigation of HuMOLYTE® as a supportive nutrition strategy for chemotherapy-related mucositis."
More on Michimich.com
The authors noted that chemotherapy-induced mucositis remains an area of high unmet need, with few consistently effective preventive therapies available. The study concluded that an oral rehydration mix containing 2′-fucosyllactose HMO and electrolytes may have potential as a food-grade approach to supporting oral hydration and electrolyte repletion during chemotherapy.
IGH Naturals emphasizes that the findings are based on animal and in vitro studies. HuMOLYTE® is not intended to diagnose, treat, cure, or prevent disease. Patients should speak with their oncology care team before adding any medical food or nutrition product during cancer treatment.
IGH Naturals is a nutrition-focused company developing science-backed medical foods and supportive nutrition products for people facing complex health challenges. HuMOLYTE® is the company's medical food formulated to support hydration and electrolyte repletion with 2′-fucosyllactose, magnesium, sodium, and potassium.
Chemotherapy-induced mucositis is a common and difficult side effect of cancer treatment that can affect the mouth and gastrointestinal tract. It may contribute to painful oral symptoms, diarrhea, dehydration, electrolyte loss, poor nutrition, and interruptions in treatment. For patients and caregivers, these complications can add physical and emotional strain during an already challenging time.
More on Michimich.com
- CRG Awarded NASA SEWP VI Contracts in Categories B and C
- Heidi G. Villari of The Villari Firm, PLLC Named to Super Lawyers for the Tenth Consecutive Year
- Elevate Your Sneakers With Crep Protect Trek Laces
- Meet Privateer: Tucson's High-Tech Security Force Built With Paramilitary Precision
- Dynamic Dachshund Dog Goes Global: Remember Point Launches a New Bilingual Children's Book
The newly published study evaluated HuMOLYTE® in Wistar rats exposed to commonly used chemotherapy agents, including doxorubicin, irinotecan, 5-fluorouracil, and cisplatin. According to the publication, HuMOLYTE® supplementation was associated with reduced severity of chemotherapy-induced diarrhea, less chemotherapy-associated weight loss, and preservation of gastrointestinal mucosal structure, including goblet cells.
The study also reported reduced inflammation in ileal, colonic, and oral mucosal tissue among animals supplemented with HuMOLYTE®. In laboratory cell studies, HuMOLYTE® improved goblet cell survival, supported mucin secretion, and helped maintain epithelial barrier function.
"This publication marks an important milestone for IGH Naturals and HuMOLYTE®," said Dr. Sourabh Kharait, corresponding author of the study. "While these findings are preclinical and require confirmation in human clinical trials, they provide a strong scientific foundation for further investigation of HuMOLYTE® as a supportive nutrition strategy for chemotherapy-related mucositis."
More on Michimich.com
- DARPA Selects NRx Pharmaceuticals Defense Subsidiary for Contract Negotiations on FDA-Authorized SPARC-TMS Clinical Trial Advancing Mental Health Care
- Tano Jones Revelry Brings Storyteller Soul Music And Community Impact To Every Stop On Their Tour
- From the Racetrack to the Boardroom: Aston Martin and Aramco Formula One Partnership Accelerates Circle8 Group: (N A S D A Q: CIRC)
- Crystals, Fossils and Family Fun Headline 80th Greater Detroit Gem, Mineral & Fossil Show
- U.N. Committee Reiterates Forced Psychiatric Detention a Human Rights Violation; CCHR Calls on the U.S. to Implement Protections
The authors noted that chemotherapy-induced mucositis remains an area of high unmet need, with few consistently effective preventive therapies available. The study concluded that an oral rehydration mix containing 2′-fucosyllactose HMO and electrolytes may have potential as a food-grade approach to supporting oral hydration and electrolyte repletion during chemotherapy.
IGH Naturals emphasizes that the findings are based on animal and in vitro studies. HuMOLYTE® is not intended to diagnose, treat, cure, or prevent disease. Patients should speak with their oncology care team before adding any medical food or nutrition product during cancer treatment.
IGH Naturals is a nutrition-focused company developing science-backed medical foods and supportive nutrition products for people facing complex health challenges. HuMOLYTE® is the company's medical food formulated to support hydration and electrolyte repletion with 2′-fucosyllactose, magnesium, sodium, and potassium.
Source: IGH Naturals
Filed Under: Health
0 Comments
Latest on Michimich.com
- Allstream Energy Partners Returns as a Media Partner for the 2026 API Inspection & Mechanical Integrity Summit in San Antonio
- The GTI Institute of GMNF Rebrands as Institute for Confessionally Reformed Faith and Practice
- Anton R. Williams Launches New Center to Bridge Traditions Through Reformed Confessions
- PokerStars & Ladbrokes veteran buys into Finnish news media Rahapelisanomat
- Former Judge Chris Oldner Honored as Best Lawyer by "D Magazine" for 6th Straight Year
- Roofman USA Highlights Key Factors Homeowners Should Consider When Choosing a Roofing Contractor
- JMAC Highlights the Core Principles of Iaido and the Benefits of Traditional Japanese Sword Training
- CMR Mechanical Encourages Homeowners to Prep for Summer Power Outages With Reliable Generators
- Compressed Gas Technologies Highlights the Importance of Nitrogen in Additive Manufacturing
- Missouri Hemp Businesses File Federal Lawsuit Challenging HB 2641
- AdviCoach of Southeast Michigan Rebrands to AdviCoach Business Coaching
- Boston Industrial Solutions Launches New Citrine® SA1-370 Silicone Glue for Permanent Adhesion
- Northeast Airlines Launches New Asset Management Group
- The best view of your business isn't from your desk
- AI Visibility Labs LLC - Dallas Texas - July 16 2026
- NextBoat's AI-Powered Marine Marketplace Gains Momentum as Record Growth Signals an Inflection Point for Investors (N Y S E American: NXB)
- Stepping Off the Grid: Savista Retreat Announces New Experiential Packages in Jaipur for Travellers
- Where Is Your Faith The Movie and Sountrack
- Bynn Intelligence Ranks #1 in NIST Child Online Safety Evaluation for Ages 13–16
- Rev-O-Box™ Launches Reversible Shipping Box That Instantly Becomes a Premium Gift Box
